Insider Selling: Azenta, Inc. (NASDAQ:AZTA) CFO Sells 712 Shares of Stock

Azenta, Inc. (NASDAQ:AZTAGet Free Report) CFO Herman Cueto sold 712 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $40.07, for a total transaction of $28,529.84. Following the completion of the transaction, the chief financial officer now owns 23,892 shares in the company, valued at approximately $957,352.44. This trade represents a 2.89 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Herman Cueto also recently made the following trade(s):

  • On Thursday, October 17th, Herman Cueto sold 1,595 shares of Azenta stock. The stock was sold at an average price of $43.68, for a total transaction of $69,669.60.

Azenta Price Performance

Shares of NASDAQ:AZTA traded up $0.88 during trading on Thursday, reaching $45.53. 1,347,000 shares of the company’s stock traded hands, compared to its average volume of 513,855. Azenta, Inc. has a fifty-two week low of $38.82 and a fifty-two week high of $69.16. The company has a 50-day simple moving average of $45.32 and a 200-day simple moving average of $50.22.

Azenta (NASDAQ:AZTAGet Free Report) last announced its earnings results on Tuesday, November 12th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.08. Azenta had a negative net margin of 25.01% and a positive return on equity of 1.03%. The business had revenue of $170.00 million for the quarter, compared to analyst estimates of $169.66 million. During the same quarter last year, the business earned $0.13 earnings per share. The company’s revenue for the quarter was down 1.2% compared to the same quarter last year. As a group, equities analysts expect that Azenta, Inc. will post 0.4 EPS for the current fiscal year.

Institutional Trading of Azenta

Several large investors have recently made changes to their positions in the company. Hantz Financial Services Inc. purchased a new position in Azenta in the 2nd quarter valued at $30,000. Farther Finance Advisors LLC lifted its stake in shares of Azenta by 20.0% in the third quarter. Farther Finance Advisors LLC now owns 1,537 shares of the company’s stock worth $74,000 after buying an additional 256 shares in the last quarter. Benjamin F. Edwards & Company Inc. boosted its position in Azenta by 150.9% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,588 shares of the company’s stock worth $84,000 after acquiring an additional 955 shares during the last quarter. Lazard Asset Management LLC purchased a new stake in Azenta during the 1st quarter valued at about $130,000. Finally, Acadian Asset Management LLC raised its holdings in Azenta by 24.7% in the 1st quarter. Acadian Asset Management LLC now owns 2,381 shares of the company’s stock valued at $143,000 after acquiring an additional 471 shares during the last quarter. 99.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on AZTA shares. Evercore ISI lowered their price target on shares of Azenta from $53.00 to $50.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. Needham & Company LLC lowered their target price on Azenta from $69.00 to $55.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $63.60.

View Our Latest Stock Report on AZTA

Azenta Company Profile

(Get Free Report)

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.

Featured Stories

Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.